Epidemiological studies carried out with large population groups show that the high levels of ANTIOXIDANTS in blood are associated with the prevention of certain types of cancer.

Antioxidants neutralize toxic agents called free radicals to help prevent cells from being oxidately attacked.

Antioxidants and OPC's play a significant role in our health, in our wellness and the reversal of the aging process.  

Today we are suffering from more illness, allergies, aches, pains, disease and even cancer has taken on a surprising rise over the last decade.  It is more difficult for us to lose weight, we have less energy yet we are still living longer than we did last century.  But we are not living healthier. Taking anti oxidants combats excessive free radical damage.

Free radicals are a very important group of agents that stimulate cell division. The participation of free radicals in the cancerigenic process has been located both at the initial stage and during the promotion and expansion of the tumour. Consequently, ANTIOXIDANTS can reduce mutagenesis through the diminution of the DNA damaged by oxidation, inhibiting cell division. 

ONCOXIN is a nutrient specially formulated with the ANTIOXIDANTS that are the most effective ones as anticancerigenic agents and that underwent a process of MOLECULAR ACTIVATION; a process that does not change their molecular structure, but increases their ANTIOXIDIZING CAPACITY and their BIOLOGICAL ACTIVITY.

• Adults: 25 ml of Oncoxin Oral Solution every 12 hours 
• Children aged 6 and over: 12.5 ml of Oncoxin Oral Solution every twelve hours
  
  Suggested Duration of Treatment: Treatment should last a minimum of 6 months. Oncoxin Solution can be used for longer periods of time without any harmful effects.
  
  Side Effects: The side effects of ONCOXIN are mild and transient. Rarely, there can be abdominal discomfort that resolves by the second week of administration.
  
  ONCOXIN is compatible with any other treatment.

• Of the 28 parameters analysed at 0, 40, 60 and 90 days’ treatment with double therapy, 16 improved and the rest returned to normal. However, with chemotherapy alone, 16 parameters were far from normal.
• It is also very important to emphasise that, prior to treatment, patients in the research group (with ONCOXIN + VIUSID, as well as chemotherapy) presented analytical parameters (CD72, aHLADR, Ig M, Ig A, CIC and NBT) far from normal, whilst in the patients in the control group these parameters were more normal.
• In patients treated with chemotherapy alone, the defences (leukocytes, Ig G, CIC, etc.) were not normal, thus the oxidative stress in all these patients increased.
• In this clinical study with 20 stomach cancer patients and 20 patients with cancer of the large intestine, ONCOXIN + VIUSID demonstrated considerable efficacy compared to the results obtained from chemotherapy alone, apart from its side effects.

• The prostatic specific antigen (PSA) presents very low levels in all cases, from 0.02 ng/ml to 7.32 ng/ml.
• No side effects were detected.
• Safety parameters did not alter.
• There was considerable improvement in the quality of life.
• 36.8% of the patients passed from stage D to stage C after 6 months’ therapy.  

• 58.93% fewer deaths in the group treated with ONCOXIN + VIUSID, compared with the control group.
• Absence of leukopoenia in the group studied, compared with the control group where there were several cases of leukopoenia.
• Generalized infections in the control group, but not in the studied group.
• Excellent tolerance to irradiation in all the studied patients, but not in the control group.
• Psycho-affective improvements.
• Very good quality of life.
• Increase in confidence and assurance about the disease.
• Rapid, easy reintegration in social and family life.
• Increase in optimism with mental and physical quality.
• No depression.
• Better weight balance.
• Normalization in the hepatic tests of the studied patients who did not take medication for hepatic protection.
• Excellent improvement of I.K. parameter in the studied group, compared with patients in the control group.
• Improvement in all biological parameters.

• Increase in adherence to the treatment.
• Increase in confidence about the success of the therapy.
• Psycho-affective and quality of life improvement.
• No depressive cases.
• Doctors’ confidence in the combination of both treatments.
• Fewer psychological services.
• Oncological treatment was easy to bear because the multiple side effects were reduced.
• Better quality of life and better Karnofsky index.
• Weight improvement in the studied group.
• Better tolerance to chemotherapy.
• Improvement in digestive consequences (nausea, etc.).
• Noticeable reduction of leukopoenia from cytostatic treatment in the studied group.
• In the studied group, 42.85% of the patients in stage IV died, as against 83.33% in the control group.
• Increase in survival in the group of patients treated with ONCOXIN + VIUSID, in comparison
  with the control group.

• Quality of life is considerably better.
• Depressions and difficulties diminish.
• Better social insertion.
• Increase in confidence and in the efficacy of the treatment and a more optimistic, positive attitude.
• Oncological treatment better sustained with considerable reduction in the frequency and intensity of side effects.
• Weight development is clearly better (2.36 times higher) in the group treated, compared with the control group.
• Better tolerance to chemotherapy, avoiding interruption in the treatment.
• Better tolerance to irradiation which progresses during the study.
• Despite radiotherapy, reduction in the intensity of skin erythema, dysphagia, mucosity and other types of erythema in comparison with the control group.
• Episodes of leukopoenia are 3.5 times less frequent in the treated group.
• In 86.66% of the studied patients, the Karnofsky index did not worsen for 12 months after treatment, compared with 46.67% in the control group.
• Improvement in all clinical and biological parameters, permitting uninterrupted radiotherapy treatment.
• 50% reduction in deaths with ONCOXIN+VIUSID, compared with the control group.